Czech and international updates in the treatment and research of chronic myeloid leukaemia
Authors:
N. Čuřík 1,2
Published in:
Transfuze Hematol. dnes,31, 2025, No. 1, p. 41-44.
Category:
Letters to Editor
Overview
This article presents a selection of information shared at professional events held in the Czech Republic in September 2024, focusing on the treatment and research of chronic myeloid leukaemia.
Keywords:
chronic myeloid leukaemia – real-world data – asciminib – treatment-free remission (TFR)
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2025 Issue 1
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
Most read in this issue
- Vitamin D and its importance in lymphomas
- Cardiovascular complications that may be caused by anti-myeloma drugs
- Levels and signifi cance of vitamin D in patients with malignant lymphomas
- Aktualita z kongresu ASH 2024 Molekulární genetika určuje směr léčby AML